ABSTRACT TGF-b is a potent suppressor of T cell activation and expansion. Although the antiproliferative effects of TGF-b are well characterized in TCR-activated cells, the effects of TGF-b on T cell proliferation driven by homeostatic cytokines, such as IL-7, are poorly defined. In the current study, we found that TGF-b inhibits IL-7-induced proliferation in memory, but not in naive human CD4 + T cells.
Introduction
TGF-b1 is a cytokine that affects various cellular activities, including proliferation, differentiation, and apoptosis [1] . TGF-b has well-defined immunosuppressive effects on the immune system [2] [3] [4] [5] [6] [7] and is therefore important in protection from immunopathology. Deficiencies in TGF-b receptor expression can lead to T cell hyperactivation [8, 9] , whereas inhibition of TGF-b during parasitic infections may lead to poorly controlled immunopathology [10] . Overexpression of TGF-b can also be detrimental in certain circumstances, as TGF-b expression has been linked to susceptibility to certain parasites [11] and to impaired immune responses in tumor microenvironments [12] .
Thus, an appropriate balance in T cell exposure to TGF-b is important for efficient immune responses and homeostasis.
To mediate complex biologic effects, TGF-b signals through its receptor to activate Smad-2 and -3. Activated Smad-2/3 binds to Smad-4, and this complex translocates to the nucleus to regulate gene transcription [13, 14] . Cellular responses to TGF-b are complex and may be determined by expression of cell-typespecific cofactors [15] [16] [17] , TGF-b receptors, signaling pathway regulators, and epigenetic mechanisms [18] . Although there are multiple levels of complexity by which TGF-b affects cell responses, various studies have defined TGF-b signaling through Smad-3 as a potent suppressor of proliferation in epithelial cells, keratinocytes, and TCR-activated T cells [19] [20] [21] . In epithelial cells and keratinocytes, TGF-b arrests the cell cycle at the G1-S phase transition by down-regulating c-myc expression [22] , which is a key determinant in cell cycle progression [23, 24] . In TCR-activated T cells, TGF-b suppresses the expression of metabolic genes and diminished mTORC1-mediated S6 kinase activity [19] . Early studies also suggested that TGF-b could impair JAK/STAT signaling in T cells stimulated with IL-2 [25] ; however, this observation was later disputed [26] . The collective results of these studies suggest that TGF-b inhibits the induction of c-myc expression and the cellular metabolic program to impair cellular proliferation.
Despite our understanding of the activity of TGF-b in TCRactivated cells, the potential importance of this cytokine in T cells, responding to homoeostatic cytokines such as IL-7, is poorly defined. Recent studies in mice with deficiencies in TGF-b receptor demonstrated that these mice had a loss of naive T cells and a corresponding decrease in expression of IL-7Ra [27] . This observation raises the possibility that TGF-b has differential effects on naive and memory T cells, particularly in the context of IL-7 stimulation. Because IL-7 is a critical mediator of T cell restoration in lymphopenic conditions and has a nonredundant role in sustaining T cell numbers in the periphery [28] , the potential interactions of TGF-b with IL-7 represent an important consideration in T cell homeostasis.
IL-7 signals through the IL-7 receptor and comprises IL-7 receptor a (IL-7Ra or CD127) and the common g chain (gc or CD132) [29] . IL-7 receptor engagement activates JAK-1 and -3, leading to STAT-5 phosphorylation and subsequent expression of genes promoting cell survival [30] . Additional signaling through PI3K is activated by IL-7, resulting in delayed phosphorylation and activation of Akt [31, 32] and S6 [33] , the 40s ribosomal subunit. Phosphorylation of S6 is associated with increased protein translation [34] , whereas p-Akt inactivates the negative regulator of proliferation, glycogen synthase kinase (GSK)-3 [35] . In resting cells, GSK-3 is a constitutively active kinase that interacts with many kinases [36] and promotes the degradation of c-myc [37] . Thus, IL-7 promotes c-myc expression and global protein translation to drive cellular proliferation.
In this study, we examined the effects of TGF-b on human naive and memory T cell proliferation that is induced by IL-7. We found that TGF-b inhibits IL-7-induced memory, but not naive T cell proliferation. We also uncovered differential effects of TGF-b on S6 signaling and the duration of c-myc inhibition in IL-7-stimulated memory and naive T cells. Furthermore, we find that chemical inhibition of GSK-3 at least partially overcomes TGF-b-mediated inhibition of c-myc expression and proliferation in IL-7-stimulated memory T cells. Overall, our studies highlight striking differences in the effects of TGF-b on IL-7 responses in naive and memory T cells, suggesting that TGF-b plays a differential role in the homeostasis of these cellular subsets.
MATERIALS AND METHODS

PBMCs and CD4
+ T cell subset isolation 
RESULTS
TGF-b inhibits memory but not naive CD4 + T cell proliferation in response to IL-7
To characterize the effects of TGF-b on naive and memory CD4 T cells, respectively. We found that TGF-b inhibited proliferation in purified CD45RA 2 memory T cells that were further defined by expression of CD27 + (CM cells) and CD27 2 (EM cells) (Fig.   1D ). In contrast, TGF-b did not inhibit proliferation of purified naive T cells stimulated with rIL-7.
TGF-b suppresses IL-7-mediated induction of c-myc expression in naive and memory CD4 + T cells
In keratinocytes and epithelial cells, TGF-b has been found to inhibit cell proliferation in an Smad-3-dependent manner by suppressing c-myc transcription [21] . To test whether TGF-b inhibits IL-7-induced c-myc expression in T cells, we stimulated PBMCs with IL-7 6 TGF-b and measured intracellular c-myc protein by flow cytometry. In preliminary studies, we found evidence that IL-7 mediated up-regulation of c-myc expression in CD4 + T cells within 3-5 d of stimulation (data not shown). At poststimulation day 5, IL-7 treatment caused some cells to increase in size (defined by increased forward scatter by flow cytometry) in the CD4 + T cell maturation subsets, corresponding to increased expression of c-myc. Both IL-7-mediated c-myc upregulation and increased cell size were diminished by TGF-b treatment in naive and memory CD4 + T cell subsets ( Fig. 2A and  B) . The magnitude of c-myc inhibition was compared among the T cell subsets at days 3 and 5 after stimulation with IL-7+TGF-b . Whereas similar levels of inhibition were noted at 3 d post stimulation among the T cell subsets, naive T cells tended to display a lesser degree of TGF-b-mediated inhibition at poststimulation 5 d, compared to memory cells and particularly compared with EM cells. This finding suggests that the inhibitory effect of TGF-b on c-myc expression diminished more substantially over time in the naive T cell subset compared with the memory subsets (Fig. 2C) . Nonetheless, TGF-b inhibited induction of IL-7-induced c-myc expression in all T cell subsets.
TGF-b does not inhibit IL-7 receptor signaling in memory CD4
+ T cells and enhances S6 kinase signaling in naive CD4 + T cells
We and others have shown that p-Akt signaling in response to IL-7 is delayed and important to proliferation [31, 32] . Phosphorylation of S6 is downstream of p-Akt and promotes proliferation by increasing protein translation [33] . TGF-b has been shown to inhibit S6 kinase phosphorylation and activity in TCR-activated CD4 + T cells [19] . To further examine the mechanism for the differential effects of TGF-b on proliferation in response to IL-7 between the CD4 + T cell maturation subsets, we assessed the effects of TGF-b on the induction of p-STAT-5 and p-S6 in response to IL-7 at poststimulation 3 d. This time point was chosen based on our previous experience with IL-7-induced p-Akt signaling that becomes detectable by flow cytometry 2-3 d after IL-7 stimulation [32] (Fig. 3A) . Nguyen and Sieg TGF-b inhibits IL-7-induced proliferation www.jleukbio.org independent of Akt, given that we did not see a consistent effect of TGF-b on Akt signaling in any T cell subset (Fig. 3B) . Overall, TGF-b had no discernible effects in memory T cell subsets but enhanced p-S6 signaling in naive T cells.
We considered the possibility that TGF-b may enhance CD127 expression in naive T cells as a means to increase S6 signaling in these cells. Using PBMCs from 3 donors, we evaluated CD127 receptor expression in CD4 + T cell subsets that had been incubated for 3 d in the presence of IL-76TGF-b. Compared to cells incubated in medium alone, CD127 cell surface density was not affected by incubating cells in TGF-b but was downregulated in cells incubated with IL-7. The addition of TGF-b to IL-7-stimulated cells tended to cause further loss of CD127 expression (Supplemental Fig. 2) . Notably, we found that IL-7 receptor occupancy, resulting from treating freshly isolated PBMCs with high concentrations of rIL-7 (75 ng/ml) for 1 h on ice, had little effect on CD127 detection, suggesting that the loss of CD127 observed in these studies was not simply due to receptor occupancy that interfered with antibody-receptor interaction (data not shown). Thus, TGF-b did not appear to enhance CD127 cell surface expression, either alone or in combination with IL-7 in any CD4 + T cell subset.
GSK-3 inactivation partially overcomes TGF-b-mediated inhibition of IL-7-induced proliferation and c-myc induction in memory CD4 + T cells P-Akt phosphorylates GSK-3, resulting in its inactivation in response to IL-7 stimulation. Since GSK-3 constitutively promotes c-myc degradation, inactivated GSK-3 results in increased c-myc expression [35] . Therefore, we asked if a chemical inhibitor of GSK-3 might overcome TGF-b-mediated inhibition of T cell proliferation and c-myc suppression in IL-7-stimulated memory T cells. CHIR-99021 (CH) is a highly specific small molecular inhibitor of GSK-3a and -3b isoforms, which inactivates GSK-3 by competitive ATP binding [38] . We assessed T cell proliferation percentage of CFSE low cells) in response to IL-7 6 TGF-b, in the presence or absence of CH. The addition of CH to the PBMCs resulted in modest increases in memory T cell proliferation compared to cells incubated in medium alone, and CH also increased proliferation in cells stimulated with IL-7 (Fig. 4A) .
The addition of CH to cells treated with IL-7+TGF-b resulted in proliferation responses that were greater than those observed in cells treated with IL-7+TGF-b and in the case of CM cells, similar to the responses observed in T cells stimulated with IL-7 alone (Fig. 4A and B) . Thus, CH largely overcame the TGF-b-mediated inhibition of IL-7-induced proliferation in the CM CD4 + T cell subset and partially overcame the inhibition of proliferation in the EM CD4 T cell subset ( Fig. 4A and B) . Similarly, CH reversed the TGF-b-mediated inhibition of c-myc expression in CM CD4 + T cells and partially reversed inhibition EM CD4 + T cells at days 3 and 5 following IL-7 stimulation (Fig. 4C) . In comparison to cells stimulated with rIL-7 and TGF-b, cells stimulated with IL-7+TGF-b+CH displayed significantly improved proliferation responses measured by percentage of divided cells within the CM subset (Fig. 4D) . A tendency toward improvement in proliferation indices also was noted in memory subsets (comparing IL-7+TGF-b to IL-7+TGF-b+CH) although this effect did not reach statistical significance (Supplemental Fig. 3) . Notably, proliferation of T cells stimulated with CH GF-b+IL-7 was consistently lower than proliferation of cells stimulated with CH+IL-7 ( Fig. 4A and data not shown), suggesting that some antiproliferative effects of TGF-b remained in the presence of CH. Although the purpose of the above experiments was to determine the effect of the GSK-3 inhibitor, CH, on memory T cells, we also found striking effects of the inhibitor in naive T cells. For example, at the concentration of CH (1 mM) used to overcome TGF-b inhibition in memory T cells, we found that CH alone markedly induced naive T cell proliferation (median percentage of CFSE low cells = 34% in CH-treated PBMCs after 7 d; n = 6; Fig. 4D) . Moreover, the addition of CH to IL-7-stimulated PBMCs induced marked proliferation in naive T cells that far exceeded the proliferation observed in cells stimulated with IL-7 alone (medium percentage of CFSE low = 18% and 86%, for naive T cells stimulated with IL-7 or IL-7+CH, respectively, n = 6; P = 0.0313). These observations suggest that GSK-3 plays a more critical role in regulating proliferation in naive T cells than memory T cells.
DISCUSSION
Differential effects of TGF-b on naive and memory CD4 T cell proliferation has been described previously in T cells activated by anti-CD3 plus IL-2. In these studies, TGF-b inhibited memory, but enhanced naive TCR-driven proliferation, in the presence of IL-2 but not in the presence of IL-7. The TGFb-mediated enhancement of proliferation in naive CD4 + T cells was associated with increased IL-2Ra (CD25) expression [39] . Our data also point to differences in the effects of TGF-b on proliferation in naive and memory T cells. Our studies did not include TCR stimulation and centered instead on the direct effects of TGF-b on T cell proliferation in response to the homeostatic cytokine IL-7. We find that TGF-b impairs memory but not naive CD4 + T cell responses to IL-7 stimulation. One limitation of our study was that we did not include analyses of T reg cells, which may have either naive or memory phenotype and may respond differently to either TGF-b or IL-7 stimulation compared to conventional T cells. TGF-b induces FOXP3 expression and mediates T reg cell differentiation T cell cultures [40, 41] . Studies in TGF-b and -bRII knockout mice suggest that TGF-b has an important role for T reg cell homeostasis and maintenance [42, 43] . Thus, it is possible that TGF-b could affect T reg in a manner that is distinct from conventional T cells. Moreover, although human T regs have limited CD127 expression, these cells are still able to mount responses to rIL-7 stimulation in vitro [44] and recent data suggest that IL-7 may play a role in thymusindependent maintenance of naive T regs in persons experiencing thymectomy [45] . Thus, further studies that explore the possible interactions of TGF-b and IL-7 in naive and memory T reg cell homeostasis may uncover additional complexities.
Because TGF-b inhibits c-myc expression in epithelial cells [21] , we speculated that a similar effect may occur in T cells. We further hypothesized that inhibition of T cell proliferation would correspond to inhibition of c-myc expression and therefore may be more pronounced in memory CD4 + T cells than in naive CD4 + T cells. Our data demonstrate that the TGF-b mediates inhibition of c-myc expression in both memory and naive T cells; however, it only impairs proliferation of memory CD4 + T cells. The reason behind this observation is unclear but may be related to the TGFb-mediated increase in p-S6 induction in response to IL-7 in naive but not memory CD4 + T cells (Fig. 3) . [26] . We found unexpected evidence that TGF-b could enhance IL-7-induced p-S6 signaling in naive T cells. The mechanism underlining this effect of TGF-b is uncertain but may be related to the reported role of TGF-b in enhancing CD127 expression in naive T cells [27] . Nonetheless, in preliminary experiments, we did not find consistent evidence of higher CD127 expression in naive T cells incubated with TGF-b compared to unstimulated cells (data not shown), and we found no evidence of higher CD127 expression in cells incubated with TGF-b+IL-7 compared to cells incubated with IL-7 alone (Supplemental Fig. 2) . Also, we did not find a consistent enhancement of p-Akt signaling or p-STAT-5 signaling in naive T cells exposed to IL-7+TGF-b compared with IL-7-stimulated cells alone. These observations suggest that the effects of TGF-b on p-S6 signaling in naive T cells may occur independently of effects on CD127 expression. Further studies with more detailed kinetic and dose-response analyses of CD127 expression and signaling pathway activation may ultimately help to discern the mechanism behind this effect.
The importance of IL-7 and TGF-b in maintaining T cell homeostasis have been highlighted in mouse models, where IL-7 deficiency results in T cell lymphopenia [28] , whereas loss of TGF-bR results in T cell hyperactivation [8, 9] . Moreover, in mice, TGF-b plays an important role in enhancing naive T cell survival by sustaining CD127 expression. This effect involved suppression of Gfi-1, a regulatory factor that reduces CD127 transcription [27] . Thus, although recognized for its immunosuppressive activities, there is a growing appreciation that TGF-b plays an important role in sustaining the number of naive T cell in vivo.
The interplay between IL-7 and TGF-b may also be important in inflamed lymph node microenvironments, such as those observed in HIV disease. Memory and naive CD4 + T cells are exposed to IL-7 expressed by stromal cells in reticular networks within the lymph node [46] [47] [48] , and TGF-b may be secreted from activated or regulatory T cells during HIV infection [2, 49] [46] . Thus, memory CD4 + T cells that rely on IL-7 to proliferate and maintain homeostasis could be inhibited by TGF-b exposure in T cell zones within lymph nodes. Similar interactions may occur in mucosal microenvironments where IL-7 is produced by epithelial cells [50] and TGF-b may be produced by various cells [51] . It is likely that TGF-b and IL-7 interactions influence homeostasis of other cell types that rely on IL-7, such as g/d T cells [52] in the mucosa and that these interactions could also be modified in the context of inflammatory conditions. We show here that chemical inhibition of GSK-3 can at least partially overcome TGF-b-mediated inhibition of IL-7-induced memory T cell proliferation. TGF-b causes downregulation of c-myc expression via Smad-dependent transcriptional suppression, whereas GSK-3 mediates degradation of c-myc protein [21, 53, 54 ] Therefore, we speculate that GSK-3 inhibition likely overcomes TGF-b inhibition by prolonging the half-life of c-myc protein, thereby, compensating for diminished transcriptional production. An alternative, and not mutually exclusive hypothesis, is that GSK-3 inhibition may affect CD98/SLCA5 expression, leading to increased amino acid uptake, which in turn, provides a mechanism to boost protein synthesis and c-myc translation [55] . The latter has been implicated as a mechanism to enhance c-myc expression in mouse effector CTLs maintained in cell culture with rIL-2, although notably, IL-7 appeared to be far less effective at sustaining c-myc expression in these experimental conditions [56] .
It is also striking that chemical inhibition of GSK-3 was sufficient to induce T cell proliferation and that the effects were most pronounced among naive T cells. These data will need further study to fully understand the underlying mechanisms, and it will be interesting to explore the possibility that inhibition or disruption of GSK-3 expression in vivo may have similar effects. Taken together, our observations suggest that the role of GSK-3 in regulating IL-7 proliferation responses in T cells is likely to change as cells mature, with the most substantial effects being observed in less mature cells (naive . CM . EM). These data are consistent with previous studies indicating that CD28-mediated control of GSK-3 is more important in naive than in memory T cells that proliferate in response to TCR triggering. Our studies also raise the intriguing possibility that targeting GSK-3 for inhibition in vivo is a strategy to at least partially circumvent TGFb-mediated inhibition of memory T cells. This strategy may be desirable, for example, to enhance T cell responses to tumors or pathogens. It may be limited, however, by the potential for TGF-b to enhance production of other immunosuppressive cytokines such as IL-10 in memory T cells [57] .
Overall, our studies uncover novel interactions of TGF-b and IL-7 that have distinct implications for naive and memory T cell proliferation and homeostasis. Our studies with human T cells are consistent with studies in mice, suggesting that TGF-b plays an important role in maintaining naive T cell homeostasis while limiting memory T cell expansion under steady state conditions. Understanding the molecular mechanisms that account for these differential outcomes may ultimately be important for designing intervention strategies that support T cell recovery from lymphopenia while inhibiting T cell hyperactivation in vivo.
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